Trump official on defensive as critics scoff at drug plan image

The Hill , May 19, 2018
Peter Sullivan, quoting Rachel Sachs (Academic Fellow Alumna)


Read the Full Article

From the article:

President Trump's health chief is struggling to show that the administration is serious about taking on drug companies after its proposals for lowering prices last week left big companies relieved and even spurred an uptick in their stock prices.

Secretary of Health and Human Services Alex Azar insists that the companies are misreading the administration's plan and that it will bring down drug prices.

“There was little in the President’s speech or in the blueprint that took direct aim at industry, despite the president’s tough talk against pharmaceutical company pricing practices,” Rachel Sachs, a drug pricing policy expert at Washington University in St. Louis, wrote in Health Affairs.

Read the full article here!

pharmaceuticals rachel sachs regulation